Editorial Team

AN IDC Breast Cancer Survivor’s Journey: From Diagnosis to Triumph

A healthy 40-year-old woman with no family history of cancer noticed a lump in her right breast months after breast implants. Diagnosed with invasive ductal carcinoma, she underwent multiple treatments, including surgery, chemotherapy, targeted therapy, and innovative immunotherapy. Despite the challenges, she achieved no evidence of disease (NED), proving the power of personalized treatment approaches.

AN IDC Breast Cancer Survivor’s Journey: From Diagnosis to Triumph Read More »

Bevacizumab: The Angiogenesis Inhibitor Redefining Cancer Care

Bevacizumab (Avastin) has transformed cancer treatment since its approval in 2004, offering new hope to patients with advanced cancers. This targeted therapy works by inhibiting vascular endothelial growth factor-A (VEGF-A), a key protein that fuels tumor growth by promoting new blood vessel formation. By blocking VEGF-A, bevacizumab cuts off a tumor’s blood supply, slowing its

Bevacizumab: The Angiogenesis Inhibitor Redefining Cancer Care Read More »